The Pediatric Vision Therapy Market — Why Children's Eye Care Is a $6.6 Billion Opportunity

One in twenty children has a binocular vision disorder that affects learning. Fewer than half get screened before school. The gap between prevalence and treatment is creating a multi-billion dollar market — and a generation of kids falling through the cracks.

There is a number that should keep every pediatrician, school administrator, and health policy maker up at night: ten. That is the number of US states with no vision screening requirements for children at all. Not inadequate requirements. None.

In the remaining forty states, most mandate only a basic distance acuity check — the Snellen chart, read from across the room. It catches myopia. It misses almost everything else. Binocular vision disorders, accommodative dysfunction, convergence insufficiency, tracking problems — the conditions that actually make it hard for a child to read, focus, and learn — sail through a 20/20 screening completely undetected. Studies suggest these screenings miss up to 75 percent of the vision problems that impair academic performance.

The result is a pediatric vision therapy market defined less by the patients it serves than by the vastly larger population it does not reach. Industry analysts estimate the amblyopia treatment market alone at roughly $6.6 billion in 2025, with forecasts reaching $8.6 billion by 2032. Add the strabismus treatment apparatus market — $1.65 billion in 2025, growing at nearly 7 percent annually — and you begin to see the contours of an opportunity that is both enormous and largely unmet.

The Conditions Hiding Behind 20/20 Vision

To understand why the pediatric vision therapy market is so underserved, you need to understand what school screenings are actually measuring — and what they are not.

Amblyopia affects 1 to 4 percent of American children, depending on the study population. Often called "lazy eye," it is a neurodevelopmental condition where the brain favors one eye over the other, leading to reduced visual acuity that cannot be corrected with glasses alone. If caught early — ideally before age seven, though recent research is pushing that window — amblyopia is highly treatable. If missed, it can cause permanent vision impairment. The Baltimore Pediatric Eye Disease Study found that only about 40 percent of three-year-olds receive any vision screening, and an Alabama study put that figure at just 12 percent. The children who slip through are not edge cases. They are the norm.

Strabismus — misalignment of the eyes — affects 2 to 5 percent of children. It is often visible, which means detection rates are higher than for other binocular vision disorders. But treatment decisions are complicated by a longstanding debate between surgical correction (the ophthalmology standard) and vision therapy approaches. The strabismus treatment market is projected to reach $2.16 billion by 2029, with the non-surgical segment showing the strongest growth as more families seek alternatives to operating room interventions for young children.

Convergence insufficiency is the stealth condition. It affects 4 to 6 percent of school-age children — meaning in a classroom of 25, at least one student is likely struggling with it — but it produces no visible symptoms. A child with convergence insufficiency can see perfectly well at distance. Their eyes simply cannot sustain the inward turn needed for sustained near-focus work: reading, writing, tablet use. The symptoms look exactly like attention problems: difficulty concentrating, losing place while reading, headaches after homework. Many of these children are evaluated for ADHD before anyone checks their binocular vision.

This is the condition where the evidence for vision therapy is strongest. The Convergence Insufficiency Treatment Trial, a multicenter NIH-funded randomized controlled trial, demonstrated that 73 percent of children receiving office-based vision therapy achieved normal or significantly improved convergence. Pencil push-ups — the most commonly prescribed home exercise — performed no better than placebo. The science is settled. The access is not.

The Treatment Gap in Numbers

The fundamental challenge of the pediatric vision therapy market is not insufficient demand. It is the chasm between how many children need care and how many actually receive it.

Consider the math. Roughly 74 million children live in the United States. At a conservative 5 percent prevalence for binocular vision disorders (combining amblyopia, strabismus, and convergence insufficiency with some overlap), approximately 3.7 million children have a condition that vision therapy could address. At current treatment costs of $2,000 to $6,000 per patient, the total addressable domestic market for pediatric vision therapy services alone ranges from $7.4 billion to $22 billion.

Yet fewer than 1,000 optometrists in the entire country offer in-office vision therapy. The provider shortage creates geographic deserts that map predictably onto existing healthcare access disparities — rural communities, low-income neighborhoods, and communities of color bear the heaviest burden of untreated pediatric vision problems.

Insurance compounds the problem. Most medical plans cover diagnostic evaluations but not the therapy itself. A typical course of vision therapy runs 20 to 40 sessions at $100 to $250 per visit. For a family paying out of pocket, that is a $2,000 to $10,000 commitment — a price that makes effective treatment a luxury rather than a right. The CITT proved that office-based therapy works. Nobody proved that families can afford it.

Digital Therapeutics Are Changing the Equation

The most significant development in the pediatric vision therapy market is not happening in optometry offices. It is happening on screens.

In 2021, Luminopia received FDA clearance for Luminopia One, a prescription digital therapeutic that treats amblyopia by modifying TV and movie content in real time, presenting different images to each eye through a VR headset to promote binocular vision development. In April 2025, Luminopia expanded its clearance to children ages 4 through 12, covering the critical treatment window. And in May 2025, Anthem Blue Cross Blue Shield became the first major insurer to cover Luminopia — a landmark that signals the beginning of payer acceptance for digital vision therapy.

That single coverage decision may matter more than any clinical trial. The historical barrier to vision therapy insurance coverage has been the classification of VT as "experimental" or "not medically necessary." An FDA-cleared digital therapeutic with major insurer coverage fundamentally changes that argument. Other payers will follow or be pressured by patients and providers who can now point to a precedent.

Beyond Luminopia, the digital therapeutics landscape for pediatric vision therapy is expanding rapidly. AmblyoPlay offers a gamified platform for amblyopia, strabismus, and convergence insufficiency treatment directly to consumers. Vivid Vision provides VR-based therapy through both clinical and home-based models. NovaSight's CureSight technology uses eye tracking to deliver dichoptic therapy. Collectively, digital platforms are estimated to account for a growing share of treatment modalities in pediatric vision care.

These tools do not replace clinical vision therapy. A child with complex strabismus still needs a developmental optometrist. But they extend the reach of treatment into homes, schools, and primary care settings that would never have a dedicated vision therapy suite — and they provide the kind of objective, trackable data that insurance companies need to justify coverage decisions.

The Screening Reform That Could Unlock the Market

If digital therapeutics represent the supply-side breakthrough, screening reform represents the demand-side catalyst.

The evidence for comprehensive vision screening — as opposed to simple acuity testing — has been building for decades. The Pediatric Eye Disease Investigator Group (PEDIG) has generated a substantial body of research demonstrating that early detection dramatically improves outcomes. Their finding that two hours of daily patching produces results comparable to six hours was not just a clinical insight — it was a compliance breakthrough that made treatment practical for families.

Several states have already moved beyond basic acuity screening. Illinois, Kentucky, and Nebraska mandate comprehensive eye exams before school entry. Missouri requires screening for near vision and eye alignment in addition to distance acuity. Each state that strengthens its screening requirements instantly expands the diagnosed patient population — and with it, the demand for treatment.

The American Optometric Association continues to advocate for InfantSEE, a public health program providing free comprehensive eye assessments for infants six to twelve months old. But uptake remains limited, partly because most parents and pediatricians do not know it exists, and partly because the referral pathway from screening to treatment remains fragmented.

The market opportunity is not just in treatment. It is in building the infrastructure that connects screening to diagnosis to treatment to outcomes — an integrated pathway that barely exists today.

What the Growth Trajectory Looks Like

The pediatric vision therapy market is being reshaped by four converging forces:

Regulatory momentum. FDA clearances for digital therapeutics create legitimate, reimbursable treatment options. Each clearance builds the evidentiary case for the next one.

Insurance evolution. The Luminopia-Anthem deal is a proof point that digital VT can navigate the payer landscape. As more outcomes data accumulates, coverage will expand from amblyopia to convergence insufficiency and beyond.

Screening reform. State-level legislative action on comprehensive vision screening will increase diagnoses, which increases demand for treatment. This is a slow-moving but powerful tailwind.

Parental awareness. The internet has done what decades of professional advocacy could not — made parents aware that their child's reading difficulty might be a vision problem, not a motivation problem. Search volume for "convergence insufficiency" and "vision therapy near me" has grown steadily for five consecutive years.

The amblyopia treatment market's projected growth from $6.6 billion to $8.6 billion by 2032 — a 3.8 percent CAGR — may actually understate the trajectory if digital therapeutics adoption and screening reform accelerate faster than the baseline models assume.

For eye care providers, the implications are clear. Practices that invest in pediatric vision therapy services today are positioning for a market that is being structurally expanded by technology, regulation, and public awareness. The children who need this care have always been there. The system is finally starting to find them.

This is the second article in a five-part series examining the vision therapy market. Read the series overview: "The Vision Therapy Market Is Bigger Than Anyone Thinks."